Low-cost compounded semaglutide is available, but the formulation, testing, and quality controls vary between providers
Trial registration This trial was registered at ClinicalTrials.gov (NCT04153929) and EudraCT (2019-002390-60)
For weight management, patients receiving the higher 2.4 mg dose (Wegovy) often experience significant weight loss, with average reductions of 10-15% of body weight in obesity treatment trials, while lower doses used for diabetes typically produce more modest weight loss
Dont leave it off your screening forms: This information directly affects how your anesthesia is managed
Common side effects may include: Nausea Vomiting Diarrhoea Constipation Stomach discomfort Headache Fatigue Reduced appetite These side effects are generally mild to moderate and often improve as your body adjusts to treatment
This allows for more gradual dose adjustments to minimize side effects and optimize weight loss outcomes